Ablaze Pharmaceuticals
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment, serving oncology healthcare providers across the Greater China market with a pipeline built on a $75M Series A.
- Company typePrivate
- Founded2011
- HeadquartersJingan, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Ablaze Pharmaceuticals firmographics
Firmographics- Name
- Ablaze Pharmaceuticals
- Legal name
- Ablaze Pharmaceuticals
- Website
- https://ablazepharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment, serving oncology healthcare providers across the Greater China market with a pipeline built on a $75M Series A.
- Ownership category
- akta.pro rank
Ablaze Pharmaceuticals industry classification
Industry- Product category
- Radiopharmaceutical Oncology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Ablaze Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Jingan
- HQ country
- China
- HQ region
- Asia
Markets served
Ablaze Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pre-revenue Stage: Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company currently in the pre-revenue phase. The company is developing targeted radiopharmaceutical therapies for cancer and has not yet commercialized any products. Revenue generation is anticipated upon successful development and regulatory approval of TRT products in the Greater China market.
Go-to-market motion1 record
Ablaze Pharmaceuticals product offering
Product offeringCore offering
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment. The company is building a pipeline of TRT products intended to precisely target cancer cells while minimizing damage to healthy tissue, with a commercial focus on the Greater China market. Ablaze has not yet commercialized any products and remains pre-revenue.
Differentiator
Problem solved
Functional benefit
Products and services
- Targeted Radiopharmaceutical Therapy (TRT) Pipeline Clinical-stage pipeline of targeted radiopharmaceutical therapies designed to precisely target cancer cells while minimizing damage to healthy tissue, intended for oncology healthcare providers and institutions in the Greater China market upon regulatory approval.
Companies that use Ablaze Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Ablaze Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ablaze Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Ablaze Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Novartis: Global pharma with Pluvicto and Lutathera, the leading commercial radioligand therapies for oncology. Most comparable as the dominant commercial benchmark Ablaze's TRT assets would compete against or partner with.
- Bayer: Developed and markets Xofigo (radium-223), the first commercially significant radiopharmaceutical in oncology. Comparable as a broad incumbent with established radiopharma infrastructure and global commercial reach.
Direct peers
- Lantheus Holdings: Radiopharmaceutical-focused company with both diagnostic and therapeutic assets (e.g., PNT2002 prostate cancer program). Direct peer in TRT development and commercialization in oncology.
- Point Biopharma: Clinical-stage radiopharmaceutical company developing Lu-177 and Ac-225-based TRT assets for oncology, acquired by Eli Lilly for ~$1.4B in 2023. Direct peer validating strategic-acquisition demand for radiopharma platforms.
- Telix Pharmaceuticals: Clinical-to-commercial radiopharmaceutical company developing targeted diagnostic and therapeutic agents for oncology. Direct comparable in modality (TRT), pipeline stage, and commercial pathway.
- Curium: Global radiopharmaceutical company with established PET and SPECT diagnostics and emerging therapeutic capabilities. Comparable as a vertically integrated radiopharma peer.
- ITM Isotope Technologies Munich: Radiopharmaceutical company developing both diagnostic and therapeutic targeted radionuclide therapies, with proprietary isotope production capacity. Comparable in modality and integrated supply chain strategy.
- RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225 TRT for solid tumors, acquired by Bristol-Myers Squibb for ~$4.1B in 2024. Highly comparable modality focus and stage; the exit value defines the addressable valuation ceiling for early TRT peers like Ablaze.
Regional players
- Innovent Biologics: China-headquartered biopharmaceutical company with a large oncology pipeline and established commercial infrastructure in Greater China. Comparable as a regional oncology peer that demonstrates the scale and partnership dynamics Ablaze would face domestically.
- China Medical System Holdings: China-focused specialty pharma with oncology and cardiovascular franchises, including licensing activities for innovative modalities. Comparable regional player that could be a partner or competitor for novel oncology therapies in Greater China.
Market position
Customer concentration
Ablaze Pharmaceuticals social profiles
Digital presenceAblaze Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ablaze Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Ablaze Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ablaze Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ablaze Pharmaceuticals
What does Ablaze Pharmaceuticals do?
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment. The company is building a pipeline of TRT products intended to precisely target cancer cells while minimizing damage to healthy tissue, with a commercial focus on the Greater China market. Ablaze has not yet commercialized any products and remains pre-revenue.
Is Ablaze Pharmaceuticals a public or private company?
Ablaze Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ablaze Pharmaceuticals founded?
Ablaze Pharmaceuticals was founded in 2011. It employs 11 to 50 people.
Where is Ablaze Pharmaceuticals based?
Ablaze Pharmaceuticals is headquartered in Jingan, China, in the Asia region.
How does Ablaze Pharmaceuticals make money?
One revenue line is on record: pre-revenue Stage.
Who are Ablaze Pharmaceuticals's main competitors?
Broad incumbents on record are Novartis and Bayer. Direct peers are Lantheus Holdings, Point Biopharma, Telix Pharmaceuticals, Curium, ITM Isotope Technologies Munich and RayzeBio. Regional players are Innovent Biologics and China Medical System Holdings.
Does Ablaze Pharmaceuticals have an API?
No public API is recorded for Ablaze Pharmaceuticals.
What industry is Ablaze Pharmaceuticals in?
Ablaze Pharmaceuticals's product category is Radiopharmaceutical Oncology. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.